Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:albiglutide
|
| gptkbp:alternativeName |
gptkb:Eperzan
|
| gptkbp:approvalYear |
2014
|
| gptkbp:ATCCode |
A10BJ04
|
| gptkbp:contraindication |
gptkb:diabetic_ketoacidosis
type 1 diabetes |
| gptkbp:drugClass |
GLP-1 receptor agonist
|
| gptkbp:form |
powder for solution for injection
|
| gptkbp:halfLife |
about 5 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tanzeum
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:marketWithdrawalReason |
commercial reasons
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
nausea
diarrhea injection site reaction |
| gptkbp:usedFor |
gptkb:type_2_diabetes
|
| gptkbp:withdrawn |
2018
|
| gptkbp:bfsParent |
gptkb:albiglutide
gptkb:GLP-1_agonists |
| gptkbp:bfsLayer |
7
|